Notice of Compliance issued regarding Rezurock(TM) (belumosudil tablets)
Chronic GVHD is a complication that can occur following allogeneic stem cell transplantation, resulting i...
Read moreResearch & Access Updates
Survey of Alberta doctors suggests concerns about anti-Indigenous biases in health care
The Metis Nation of Alberta says many of its members have experienced racism when accessing Alberta's hea...
Read moreB.C. announces new $440 million, 10-year cancer care action planB.C. announces new $440 million, 10-year cancer care action plan
A massive $440 million, 10-year investment into a new cancer action plan was announced by the B.C. govern...
Read moreRevolutionary CAR T Therapy Now Available for Patients with Specific Cancers in Saskatchewan
Saskatchewan patients with specific cancers can now receive an innovative type of immunotherapy closer to...
Read moreNatco Pharma (Canada) Inc. announces the launch of PrNAT-POMALIDOMIDE Capsules, the first generic alternative to POMALYST® in Canada
Natco Pharma (Canada) Inc., a subsidiary of Natco Pharma Limited, announced today the launch of PrNAT-POM...
Read moreIsatuximab (Sarclisa): The negotiations are now over!
We’re thrilled to announce that negotiations between the pan-Canadian Pharmaceutical Alliance (pCPA) and...
Read more